Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
BMY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: Financial results · Company disclosure
Filed 8-K for an event or period dated 2026-10-29. Financial results; Company disclosure.
1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Access to prescription drugs. Policies related to 340B. Drug Pricing reform/implementation. Food is Medicine initiatives. Issues related to the budget and appropriations process
Public: Oct 20, 2026, 11:15 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
Public: Oct 20, 2026, 5:39 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.
Public: Oct 20, 2026, 5:04 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose
Public: Oct 20, 2026, 4:49 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Issues related to TrumpRX. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. Issues related to China WRT the BINSA bill. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Co
Public: Oct 20, 2026, 4:38 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Issues related to prescription drugs, including 340B program Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA); Issues related to Most Favored Nation (MFN)
Public: Oct 20, 2026, 3:45 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Issues around drug pricing. Regulation of Fixed dose drug combinations.
Public: Oct 19, 2026, 11:47 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Biosimilars reimbursement issues. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy. Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Prici
Public: Oct 19, 2026, 11:39 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Education regarding CMSs Initial Price Applicability Year (IPAY) 2029 proposed rule regarding the fixed-dose combination policy which would create significant disincentives for research and development, undermine FDA-recognized distinctions between therapies, and limit patient access to critical treatment options.
Public: Oct 13, 2026, 11:56 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Global Benchmark for Efficient Drug Pricing (GLOBE) Model
This final rule implements the Global Benchmark for Efficient Drug Pricing Model (GLOBE Model), a new mandatory Medicare payment model under section 1115A of the Social Security Act. The GLOBE Model will test whether a payment model that uses an alternative method for calculating Medicare Part B drug inflation rebate amounts for certain separately payable Medicare Part B drugs and biological products reduces costs for Original Medicare (OM) beneficiaries and the Medicare program while preserving quality of care. The term OM has the same meaning as Medicare fee-for-service and the traditional Medicare program.
1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: third_quarter 2026 lobbying report
Education regarding the value of biopharmaceutical innovation and related issues.
Public: Aug 4, 2026, 3:33 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: Financial results · Company disclosure
Filed 8-K for an event or period dated 2026-07-30. Financial results; Company disclosure.
1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
Access to prescription drugs. Policies related to 340B. Drug Pricing reform/implementation. Food is Medicine initiatives. Issues related to the budget and appropriations process
Public: Jul 20, 2026, 10:45 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
A Notice notice explicitly mentions the company. Read the cited text for its role.
Public: Jul 21, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.
Public: Jul 20, 2026, 7:29 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Issues related to the 340
Public: Jul 20, 2026, 6:44 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.
Public: Jul 20, 2026, 6:14 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consume
Public: Jul 20, 2026, 3:02 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
Issues around drug pricing.
Public: Jul 20, 2026, 2:35 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
Issues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Public: Jul 20, 2026, 1:59 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
BMY: second_quarter 2026 lobbying report
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
Public: Jul 9, 2026, 6:33 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 1:56 PM EST
- USAspending
- Collection in progress77 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 1:59 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:27 PM EST
- Federal Register
- Stale — refresh overdue295 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:00 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable32 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:00 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST